Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue:
License and collaboration revenue	$ 344,775
Total revenue	344,775
Operating expenses:
Research and development expenses	59,369	$ 29,900
General and administrative expenses	40,505	15,340
Total operating expenses	99,874	45,240
Income (loss) from operations	244,901	(45,240)
Other income and (expenses):
Grant Income	10,181	5,647
Research and development tax credits		286
Fair value adjustment for preferred stock tranche rights liability		1,265
Other income (expense), net	1,382	(48)
Income (loss) before income tax expense (benefit)	256,464	(38,090)
Income tax expense (benefit)	41,943	(57)
Net income (loss)	214,521	(38,033)
Cumulative dividends on Series A Preferred Stock		(249)
Accretion of redeemable convertible preferred stock to redemption value		(5,120)
Net income (loss) attributable to common stockholders	$ 214,521	$ (43,402)
Basic net income (loss) per common share	$ 6.10	$ (2.88)
Diluted net income (loss) per common share	$ 5.68	$ (2.88)
Weighted-average common shares outstanding - basic	35,181,383	15,080,266
Weighted-average common shares outstanding - diluted	37,774,790	15,080,266
Net income (loss)	$ 214,521	$ (38,033)
Foreign currency translation adjustments	(1,635)	841
Comprehensive income (loss)	$ 212,886	(37,192)
Series A Preferred Stock
Other income and (expenses):
Accretion of redeemable convertible preferred stock to redemption value		$ (5,120)